Kiyomiya K, Oh-ishi S
Jpn J Pharmacol. 1985 Oct;39(2):201-6. doi: 10.1254/jjp.39.201.
Rat pleurisy was induced by intrapleural injection of phorbol myristate acetate (PMA), a known tumor promotor and a component of croton oil. Pleural fluids at 30 min and 1 hr after PMA-injection were collected and arachidonic acid metabolites in the fluids were measured by RIA or bioassay after fractionation through reversed phase HPLC using an ODS column. The major metabolites found in the pleural fluid were 6-keto-PGF1 alpha, TXB2 and PGD2, with a small amount of PGE2. Pretreatment with 10 mg/kg indomethacin suppressed the pleural fluid accumulation and also reduced the amount of the above metabolites to the basal levels. Treatment with OKY-046, a novel thromboxane synthetase inhibitor, reduced the level of TXB2 completely, but had no effect on those of 6-keto-PGF1 alpha and PGD2, and it had no effect on pleural fluid accumulation either. The results may indicate that PGI2 plays a role for the vascular permeability increase in the early phase of pleurisy.
通过胸膜腔内注射佛波醇肉豆蔻酸酯(PMA,一种已知的肿瘤促进剂和巴豆油的一种成分)诱导大鼠胸膜炎。在注射PMA后30分钟和1小时收集胸水,并在使用ODS柱通过反相高效液相色谱法分级分离后,通过放射免疫分析(RIA)或生物测定法测量胸水中的花生四烯酸代谢产物。在胸水中发现的主要代谢产物是6-酮-前列腺素F1α、血栓素B2和前列腺素D2,还有少量的前列腺素E2。用10mg/kg吲哚美辛预处理可抑制胸水积聚,并将上述代谢产物的量降低至基础水平。用新型血栓素合成酶抑制剂OKY-046处理可完全降低血栓素B2的水平,但对6-酮-前列腺素F1α和前列腺素D2的水平无影响,对胸水积聚也无影响。结果可能表明前列环素(PGI2)在胸膜炎早期血管通透性增加中起作用。